CADL vs. CGEN, LENZ, VCXB, INMB, GNFT, GRPH, VXRT, PSTX, IPSC, and MOLN
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Compugen (CGEN), LENZ Therapeutics (LENZ), 10X Capital Venture Acquisition Corp. III (VCXB), INmune Bio (INMB), Genfit (GNFT), Graphite Bio (GRPH), Vaxart (VXRT), Poseida Therapeutics (PSTX), Century Therapeutics (IPSC), and Molecular Partners (MOLN). These companies are all part of the "biological products, except diagnostic" industry.
Compugen (NASDAQ:CGEN) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking and earnings.
12.2% of Compugen shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 9.5% of Compugen shares are owned by insiders. Comparatively, 44.6% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Compugen presently has a consensus target price of $4.00, indicating a potential upside of 109.42%. Candel Therapeutics has a consensus target price of $11.00, indicating a potential upside of 81.82%. Given Candel Therapeutics' higher probable upside, equities research analysts clearly believe Compugen is more favorable than Candel Therapeutics.
Compugen has a beta of 2.63, indicating that its stock price is 163% more volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.
In the previous week, Compugen had 1 more articles in the media than Candel Therapeutics. MarketBeat recorded 1 mentions for Compugen and 0 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.59 beat Compugen's score of 0.00 indicating that Compugen is being referred to more favorably in the media.
Compugen received 295 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 64.47% of users gave Compugen an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Compugen has higher revenue and earnings than Candel Therapeutics. Compugen is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
Candel Therapeutics' return on equity of -30.01% beat Compugen's return on equity.
Summary
Compugen beats Candel Therapeutics on 12 of the 16 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
